Literature DB >> 19774649

5-aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes.

Pim J Koelink1, Marij A C Mieremet-Ooms, Willem E Corver, Kamila Wolanin, Daniel W Hommes, Cornelis B H W Lamers, Hein W Verspaget.   

Abstract

INTRODUCTION: Epidemiological data suggests that 5-aminosalicylic acid (5-ASA), a nonsteroidal antiinflammatory drug used in the treatment of inflammatory bowel diseases, prevents colorectal cancer development in these patients, although the mechanisms remain incompletely understood. METHODS AND
RESULTS: Here we report that 5-ASA prevents growth of several colorectal cancer cell lines by interfering in the cell cycle, i.e., an S-phase and G2/M phase arrest, dependent on 5-ASA dosage and concentration, together with an increased mitotic index. In addition, prolonged cell cycle arrest by repeated 5-ASA treatment induced apoptosis and caused abnormal spindle organization leading to mitotic catastrophe, another form of cell death.
CONCLUSION: These observations illustrate that 5-ASA has chemopreventive and chemotherapeutic properties.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19774649     DOI: 10.1002/ibd.21086

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  12 in total

1.  Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia.

Authors:  Xiaotan Dou; Junhua Xiao; Ziliang Jin; Ping Zheng
Journal:  Oncol Lett       Date:  2015-06-19       Impact factor: 2.967

2.  Chemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer and colonic dysplasia: a meta-analysis.

Authors:  Xiaorong Xu; Xuanfu Xu; Yangzong Ciren; Baisui Feng; Chunhua Tao; Yujing Xia; Zhanju Liu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 3.  Mesalamine in the treatment and maintenance of remission of ulcerative colitis.

Authors:  Maggie Ham; Alan C Moss
Journal:  Expert Rev Clin Pharmacol       Date:  2012-03       Impact factor: 5.045

Review 4.  Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis.

Authors:  Sigrun Thorsteinsdottir; Thorkell Gudjonsson; Ole Haagen Nielsen; Ben Vainer; Jakob Benedict Seidelin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06-07       Impact factor: 46.802

5.  Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.

Authors:  Manisha Bajpai; Darren N Seril; James Van Gurp; Xin Geng; Janet Alvarez; Carlos D Minacapelli; Steve Gorin; Koushik K Das; Elizabeth Poplin; Jerry Cheng; Peter S Amenta; Kiron M Das
Journal:  Dig Dis Sci       Date:  2018-11-26       Impact factor: 3.199

6.  Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest.

Authors:  Anton Kuratnik; Virginia E Senapati; Rajeev Verma; Barbara G Mellone; Anthony T Vella; Charles Giardina
Journal:  Biochem Pharmacol       Date:  2012-01-25       Impact factor: 5.858

7.  5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis.

Authors:  Tom Julian Creed; Ann Caroline Williams; Steven William Dixon; Tracey Jane Collard; Eleanor May Harrisdotter Mortensson; Danny Nigel Legge; Adam Christian Chambers; Alexander Greenhough
Journal:  Br J Cancer       Date:  2021-03-30       Impact factor: 9.075

Review 8.  Colorectal cancer chemoprevention by mesalazine and its derivatives.

Authors:  Carmine Stolfi; Francesco Pallone; Giovanni Monteleone
Journal:  J Biomed Biotechnol       Date:  2012-06-04

9.  Crystal structure of methyl 2-hy-droxy-5-[(4-oxo-4,5-di-hydro-1,3-thia-zol-2-yl)amino]benzoate.

Authors:  Shaaban K Mohamed; Joel T Mague; Mehmet Akkurt; Hajjaj H M Abdu-Allah; Mustafa R Albayati
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-04-09

Review 10.  Systems-level biomarkers identification and drug repositioning in colorectal cancer.

Authors:  Hande Beklen; Esra Yildirim; Medi Kori; Beste Turanli; Kazim Yalcin Arga
Journal:  World J Gastrointest Oncol       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.